Literature DB >> 24146497

Effect of Chinese medical herbs-Huiru Yizeng Yihao on hyperprolactinemia and hyperplasia of mammary gland in mice.

Xiong Wang1, Yong-Gang Chen, Li Ma, Zhi-Hui Li, Ju-Yi Li, Xin-Guo Liu, Ji-Li Zou, Jin-Hu Wu.   

Abstract

The study investigated the pharmacodynamism and mechanism of Chinese medicinal formula-Huiru Yizeng Yihao (NO.1 HRYZ) on the model rats of hyperpro-lactinemia and the model rats of hyperplasia of mammary gland (HMG), and studied the internal connection between hyperprolactinemia and HMG.. The hyperprolactinemia rat models were established by injecting metoclopramide dihydrochloride in the back of rats. The model rat of HMG was prepared by injecting estradiol in the thigh muscle of the rats and progesterone consecutively, while the tails of rats were clipped with tongs. Rats were treated with either NO.1 HRYZ or positive control drugs for four weeks. The concentrations of sex hormone in rat serum were examined using ELISA kits, and the morphology of mammary gland tissue in all group rats was observed with microscope. NO.1 HRYZ significantly decreased prolactin (PRL) and increased estradiol (E2), progesterone (P), follicle stimulating hormone (FSH), luteinizing hormone (LH) concentrations of hyperprolactinemia rats. It decreased E2, PRL, FSH, gonadotropin-releasing hormone (GnRH), 5-hydroxytryptamine (5-HT) and increased P concentrations of HMG rat. It also eliminated hyperplasia of lobules and gland alveolus compared with the model group. Treatment with NO.1 HRYZ could significantly regulate the sex hormone disorder of hyperprolactinemia and HMG rat models, and could eliminate the formation of HMG. Hyperprolactinemia was closely correlated with HMG, and hyperprolactinemia promoted the formation of HMG.

Entities:  

Keywords:  HMG; NO.1 HRYZ; hyperprolactinemia; morphology of mammary gland; sex hormone

Mesh:

Substances:

Year:  2013        PMID: 24146497      PMCID: PMC3794387          DOI: 10.4314/ajtcam.v10i4.5

Source DB:  PubMed          Journal:  Afr J Tradit Complement Altern Med        ISSN: 2505-0044


  17 in total

Review 1.  The immune-neuroendocrine homeostatic network and aging.

Authors:  R G Goya
Journal:  Gerontology       Date:  1991       Impact factor: 5.140

2.  Inhibition of ovulation, steroidogenesis and collagenolytic activity in rabbits by sulpiride-induced hyperprolactinaemia.

Authors:  K C Lin; N Kawamura; H Okamura; T Mori
Journal:  J Reprod Fertil       Date:  1988-07

3.  Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems.

Authors:  Dong-Yun Lee; Yoon-Kyung Oh; Byung-Koo Yoon; DooSeok Choi
Journal:  Am J Obstet Gynecol       Date:  2011-12-16       Impact factor: 8.661

Review 4.  Protein hormones and immunity.

Authors:  Keith W Kelley; Douglas A Weigent; Ron Kooijman
Journal:  Brain Behav Immun       Date:  2007-01-02       Impact factor: 7.217

Review 5.  Lactogenic hormone signal transduction.

Authors:  L Y Yu-Lee; G Luo; M L Book; S M Morris
Journal:  Biol Reprod       Date:  1998-02       Impact factor: 4.285

Review 6.  Hyperprolactinemia: etiology, diagnosis, and management.

Authors:  Peak Mann Mah; Jonathan Webster
Journal:  Semin Reprod Med       Date:  2002-11       Impact factor: 1.303

7.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

8.  Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice.

Authors:  Erin L Milliken; Rebecca K Ameduri; Melissa D Landis; Alireza Behrooz; Fadi W Abdul-Karim; Ruth A Keri
Journal:  Endocrinology       Date:  2002-09       Impact factor: 4.736

9.  [Danazol for treatment of fibrocystic mastopathy].

Authors:  J von Fallois; U Etterli-Billenkamp; E M Schindler; A E Schindler
Journal:  Zentralbl Gynakol       Date:  1995

10.  Serum oestradiol in women with and without breast disease.

Authors:  I C Bennett; J F McCaffrey; E McCaffrey; B Wyatt
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

View more
  3 in total

1.  Network pharmacology exploration reveals the bioactive compounds and molecular mechanisms of Li-Ru-Kang against hyperplasia of mammary gland.

Authors:  Shizhang Wei; Xuelin Zhou; Ming Niu; Haizhu Zhang; Xiaoyi Liu; Ruilin Wang; Pengyan Li; Haotian Li; Huadan Cai; Yanling Zhao
Journal:  Mol Genet Genomics       Date:  2019-05-03       Impact factor: 3.291

2.  Therapeutic Effect of Mongolian Medicine RuXian-I on Hyperplasia of Mammary Gland Induced by Estrogen/Progesterone through CRYAB-Promoted Apoptosis.

Authors:  Jia Liu; Jun-Fei Zhang; Guo-Hua Gong; Bin Zhang; Cheng-Xi Wei
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-27       Impact factor: 2.629

3.  Chinese massage, Tui Na, combined with herbs improves clinical symptoms and regulates sex hormones in patients with mammary gland hyperplasia.

Authors:  Dandan Li; Cheng Wang; Di Ruan; Jingjing Li; Ning Ji; Xinwen Ma; Yongtao Li; Yujiang Qu; Zhijin Xuan; Lihua Song
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.